MLV Capital assumed coverage on shares of Lpath (NASDAQ:LPTN) in a research note issued to investors on Thursday, StockRatingsNetwork reports. The firm issued a buy rating on the stock.
MLV Capital has also updated their ratings on a number of other healthcare stocks in the last week. The firm initiated coverage on shares of TransMontaigne Partners L.P.. They issued a buy rating on that stock and set a $50.00 price target. Also, MLV Capital initiated coverage on shares of NuStar Energy L.P.. They issued a hold rating on that stock. Finally, MLV Capital initiated coverage on shares of Global Partners LP. They issued a hold rating on that stock.
Lpath (NASDAQ:LPTN) opened at 4.36 on Thursday. Lpath has a 52 week low of $3.87 and a 52 week high of $6.70. The stock has a 50-day moving average of $4.93 and a 200-day moving average of $5.25. The company’s market cap is $57.5 million.
Separately, analysts at JMP Securities initiated coverage on shares of Lpath in a research note to investors on Tuesday, October 15th. They set an outperform rating and a $14.00 price target on the stock.
Lpath, Inc is a biotechnology company focused on the discovery and development of lipidomic-based therapeutics, an emerging field of medical science whereby bioactive lipids are targeted to treat human diseases.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.